Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Persistence of inflammatory and vascular mediators 5 months after hospitalization with COVID-19 infection

Melhorn J. et al, (2023), Frontiers in Medicine, 10

Constructing custom-made radiotranscriptomic signatures of vascular inflammation from routine CT angiograms: a prospective outcomes validation study in COVID-19

Kotanidis CP. et al, (2022), The Lancet Digital Health, 4, e705 - e716

Divergent trajectories of antiviral memory after SARS-CoV-2 infection

Tomic A. et al, (2022), Nature Communications, 13

A blood atlas of COVID-19 defines hallmarks of disease severity and specificity

Ahern DJ. et al, (2022), Cell, 185, 916 - 938.e58

Persistence of inflammatory and vascular damage mediators 5 months after acute COVID-19

Petousi N. et al, (2022), EUROPEAN RESPIRATORY JOURNAL, 60

Spontaneous pneumomediastinum, subcutaneous emphysema and pneumothorax in non-intubated patients with COVID-19 pneumonitis: a retrospective case note review of a single centre experience

Karwal R. et al, (2022), EUROPEAN RESPIRATORY JOURNAL, 60

Improved COVID-19 outcomes in a large non-invasive respiratory support cohort despite emergence of the alpha variant

Turnbull CD. et al, (2021), BMJ Open Respiratory Research, 8, e001044 - e001044

Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern

Skelly DT. et al, (2021), Nature Communications, 12

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Abaleke E. et al, (2021), The Lancet, 397, 605 - 612

COMBINATION FIXED-DOSE BETA AGONIST AND STEROID INHALER AS REQUIRED FOR ADULTS OR CHILDREN WITH MILD ASTHMA: A COCHRANE SYSTEMATIC REVIEW

Fries A. et al, (2021), THORAX, 76, A24 - A24

EVALUATION OF MYCOBACTERIUM TUBERCULOSIS-SPECIFIC IFN-G, TNF-A, CXCL10, IL2, CCL2, CCL7 AND CCL4 LEVELS FOR ACTIVE TUBERCULOSIS DIAGNOSIS

Fries A. et al, (2021), THORAX, 76, A27 - A28

P170 Single centre experience on idiopathic pulmonary fibrosis patient tolerance of pirfenidone; impact on nurse-led ILD helpline usage

Rathnapala A. et al, (2016), Thorax, 71, A176.1 - A176

P175 Single centre experience of the real-life impact of pirfenidone on lung function in patients with idiopathic pulmonary fibrosis

Rathnapala A. et al, (2016), Thorax, 71, A179.1 - A179

S101 Single centre experience of switching patients with idiopathic pulmonary fibrosis from pirfenidone to nintedanib

Rathnapala A. et al, (2016), Thorax, 71, A60.1 - A60

Include forthcoming?